AU2022219476A1 - Anti-s100a4 humanized antibodies, uses and methods - Google Patents

Anti-s100a4 humanized antibodies, uses and methods Download PDF

Info

Publication number
AU2022219476A1
AU2022219476A1 AU2022219476A AU2022219476A AU2022219476A1 AU 2022219476 A1 AU2022219476 A1 AU 2022219476A1 AU 2022219476 A AU2022219476 A AU 2022219476A AU 2022219476 A AU2022219476 A AU 2022219476A AU 2022219476 A1 AU2022219476 A1 AU 2022219476A1
Authority
AU
Australia
Prior art keywords
seq
antibody
amino acid
region
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022219476A
Other languages
English (en)
Inventor
Tim Buss
Jonas HALLÉN
Rizwan Iqbal HUSSAIN
Jörg KLINGELHÖFER
Darragh MACCANN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Calluna Pharma Inc
Original Assignee
Arxx Therapeutics AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arxx Therapeutics AS filed Critical Arxx Therapeutics AS
Publication of AU2022219476A1 publication Critical patent/AU2022219476A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2022219476A 2021-02-09 2022-02-09 Anti-s100a4 humanized antibodies, uses and methods Pending AU2022219476A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163147483P 2021-02-09 2021-02-09
US63/147,483 2021-02-09
PCT/EP2022/053095 WO2022171656A1 (en) 2021-02-09 2022-02-09 Anti-s100a4 humanized antibodies, uses and methods

Publications (1)

Publication Number Publication Date
AU2022219476A1 true AU2022219476A1 (en) 2023-09-21

Family

ID=80446273

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022219476A Pending AU2022219476A1 (en) 2021-02-09 2022-02-09 Anti-s100a4 humanized antibodies, uses and methods

Country Status (8)

Country Link
US (2) US20240043521A1 (https=)
EP (1) EP4291579A1 (https=)
JP (1) JP7824969B2 (https=)
CN (1) CN117480182A (https=)
AU (1) AU2022219476A1 (https=)
CA (1) CA3207703A1 (https=)
IL (1) IL304971A (https=)
WO (1) WO2022171656A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023531230A (ja) * 2020-06-30 2023-07-21 アークス セラピューティクス エーエス 全身性硬化症の治療のための抗ｓ１００ａ４抗体
EP4433084A1 (en) * 2021-11-19 2024-09-25 Lykera Biomed, S.A. Treatment and diagnosis of diseases associated to pathogenic fibrosis
CN115819577A (zh) * 2022-10-08 2023-03-21 河南赛诺特生物技术有限公司 一种抗s100a单克隆抗体及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2580240T (pt) 2010-06-14 2019-03-29 Lykera Biomed S A Anticorpos as100a4 e utilizações terapêuticas dos mesmos
GB201219487D0 (en) * 2012-10-30 2012-12-12 Cancer Rec Tech Ltd Anti-S100A4 antibody molecules and their uses
IL263272B2 (en) * 2016-06-14 2025-07-01 Merck Sharp & Dohme Antibodies to coagulation factor xi
CN107375923A (zh) * 2017-07-06 2017-11-24 北京多赢时代转化医学研究院 抗s100a4抗体在抗cd137抗体介导抗肿瘤免疫损伤中的应用

Also Published As

Publication number Publication date
EP4291579A1 (en) 2023-12-20
IL304971A (en) 2023-10-01
US12304949B2 (en) 2025-05-20
JP2024509701A (ja) 2024-03-05
CA3207703A1 (en) 2022-08-18
JP7824969B2 (ja) 2026-03-05
WO2022171656A1 (en) 2022-08-18
US20250092125A1 (en) 2025-03-20
CN117480182A (zh) 2024-01-30
US20240043521A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
AU2018233976B2 (en) Fc-optimized anti-CD25 for tumour specific cell depletion
JP7730764B2 (ja) アンタゴニスト抗ｃｄ７抗体
US20220064312A1 (en) Novel Anti-CCR8 Antibody
US12304949B2 (en) Anti-S100A4 humanized antibodies, uses and methods
JP2022514179A (ja) 新規アゴニスト抗ｔｎｆｒ２抗体分子
KR20140116525A (ko) 항cxcr3 항체
JP7843824B2 (ja) 抗体および使用方法
JP2022512905A (ja) 新規アンタゴニスト抗ｔｎｆｒ２抗体分子
US11332528B2 (en) Anti-CEACAM1 antibody and use thereof
JP7430137B2 (ja) 抗体および使用方法
KR20240006519A (ko) 항-siglec 조성물 및 이의 용도
TWI835166B (zh) 靶向pd-1和/或ox40的特異性結合蛋白及其應用
RU2782462C1 (ru) Новое антитело против ccr8
CN111704668B (zh) 抗ccr4抗体及其在治疗癌症中的应用
CN114773485A (zh) 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子
CN119661708A (zh) 靶向cd27的单克隆抗体及其用途
WO2024144803A1 (en) Humanized anti-human neurotensin receptor 1 antibodies and their uses
WO2023125652A1 (zh) 抗cd40×cldn18.2双特异性抗体及其用途
EA052903B1 (ru) Антитело к cd40, биспецифическое антитело к pd-l1×cd40 и их применение
CN118240092A (zh) 一种抗pd-l1和tigit双特异性抗体融合蛋白及其应用
CN116848144A (zh) 抗pd-l1抗体及其用途
EA049996B1 (ru) Антитело к siglec-10 (варианты)
HK40054247A (en) Novel anti-ccr8 antibody